INTELLIA THERAPEU DL-,01 WKN: A2AG6H ISIN: US45826J1051 Kürzel: NTLA Forum: Aktien Thema: Hauptdiskussion

🎈

Intellia Investors Are Dumping Stock on News of Crispr Gene-Editing Success https://www.shareandstocks.com/intellia-investors-are-dumping-stock-on-news-of-crispr-gene-editing-success/

Intellia Therapeutics Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema https://www.globenewswire.com/news-release/2022/09/01/2508902/0/en/Intellia-Therapeutics-Receives-U-S-FDA-Orphan-Drug-Designation-for-NTLA-2002-an-Investigational-CRISPR-Therapy-for-the-Treatment-of-Hereditary-Angioedema.html • NTLA-2002, an in vivo genome editing candidate designed to prevent angioedema attacks in patients with hereditary angioedema (HAE) after a single dose, is currently being evaluated in a Phase 1/2 study ...

https://www.globenewswire.com/news-release/2022/08/23/2503154/0/en/Intellia-Therapeutics-to-Present-Interim-Clinical-Data-from-Ongoing-Phase-1-2-Study-of-NTLA-2002-for-the-Treatment-of-Hereditary-Angioedema-at-the-2022-Bradykinin-Symposium.html

Intellia Therapeutics down 12% following bottom line Q2 earnings miss https://seekingalpha.com/news/3867319-intellia-therapeutics-down-12-following-bottom-line-q2-earnings-miss?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain • Intellia Therapeutics (NASDAQ:NTLA) is down 12% in Thursday morning trading after it missed analyst estimates on Q2 2022 EPS. • The company's net loss in the quarter widened ~46% to ~$100.7M compared to the prior-year period (-$1.33 per share, basic and diluted vs. $1.01). • Revenue of ~$14M, a 114% year-over-year increase, was a beat. • Intellia (NTLA) was weighed down in the quarter by a significant increase in operating expenses, which went up ~49% to $112.3M. R&D expenses alone rose 53% to ~$90.2M. • The company ended the quarter with $906.9M in cash and cash equivalents compared to compared to $1.1B on Dec. 31, 2022.

Das ist der Grund für den heftigen Kursrückgang heute: https://www.fiercebiotech.com/biotech/intellia-looks-tack-lower-dose-polyneuropathy-trial-arm-after-elevated-liver-levels

Gestern ging es halt ordentlich aufwärts ohne news (und wohl befeuert durch Alnylam). Mal schauen, wo sie sich heute 'einpendelt'.

Ich habs echt nur überflogen, also womöglich etwas überlesen. Aber warum dropped es denn so? Viel cash und nichts schlimmes was die Studien angeht. Daten in H2 22 erwartet. Hab ich was übersehen?

Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress https://www.globenewswire.com/news-release/2022/08/04/2492214/0/en/Intellia-Therapeutics-Announces-Second-Quarter-2022-Financial-Results-and-Highlights-Recent-Company-Progress.html

https://www.globenewswire.com/news-release/2022/06/24/2468698/0/en/Intellia-and-Regeneron-Present-Updated-Interim-Data-from-Phase-1-Study-of-CRISPR-based-NTLA-2001-for-the-Treatment-of-Transthyretin-ATTR-Amyloidosis-Demonstrating-that-Deep-Serum-T.html

https://www.globenewswire.com/news-release/2022/06/08/2458609/0/en/Intellia-Therapeutics-to-Present-Updated-Interim-Clinical-Data-from-Ongoing-Phase-1-Study-of-NTLA-2001-for-the-Treatment-of-Transthyretin-ATTR-Amyloidosis-at-the-International-Live.html

Intellia Therapeutics Announces First Quarter 2022 Financial Results and Highlights Recent Company Progress https://www.globenewswire.com/news-release/2022/05/05/2436692/0/en/Intellia-Therapeutics-Announces-First-Quarter-2022-Financial-Results-and-Highlights-Recent-Company-Progress.html

Intellia Therapeutics Presents Preclinical Data Demonstrating Advancements in its CRISPR-Engineered Allogeneic Platform at the 2022 Keystone Symposia’s Precision Genome Engineering Conference https://www.globenewswire.com/news-release/2022/05/02/2433370/0/en/Intellia-Therapeutics-Presents-Preclinical-Data-Demonstrating-Advancements-in-its-CRISPR-Engineered-Allogeneic-Platform-at-the-2022-Keystone-Symposia-s-Precision-Genome-Engineering.html • Data highlight proprietary allogeneic cell engineering platform capable of creating immune-evading T cells and deployable for TCR-T and CAR-T cell therapy • Findings support recent development candidate initiation of NTLA-6001, an investigational allogeneic CAR-T therapy, for the treatment of CD30-expressing hematologic cancers

Intellia's CRISPR-engineered cell therapy secures FDA orphan drug status after AML trial launch https://www.fiercebiotech.com/biotech/intellias-1st-ex-vivo-cell-therapy-aml-secures-fda-orphan-drug-status-week-after-trial

Na scheint gerade eher nach hinten los zu gehen 😂

Sehr schön! Intellia hat eben ein Press Releases veröffentlicht mit einer Stellungnahme. Liest sich für mich soweit neutral bis positiv. Ich hoffe, dass dies nun die Investoren wieder zurück holt und sich der Kurs somit auch wieder erholt.